key: cord-1005879-kd560qmr authors: Kotze, Paulo Gustavo; Peyrin-Biroulet, Laurent; Danese, Silvio title: Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic date: 2020-05-15 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.04.075 sha: 7dacff7ad57b7ce2989edda271512e9bab454cc0 doc_id: 1005879 cord_uid: kd560qmr nan P.G.K has been a lecturer for AbbVie, Janssen, Pfizer and Takeda and is a member of the advisory board of AbbVie, Pfizer and Takeda. L.P.-B. has received consulting fees from AbbVie, Amgen, Biogaran, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Ferring, Genentech, HAC Pharma, Hospira, Index Pharmaceuticals, Janssen, Lilly, Merck, Mitsubishi, Norgine, Pfizer, Pharmacosmos, Pilege, Sandoz, Takeda, Therakos, Tillotts, UCB Pharma and Vifor and lecture fees from AbbVie, Ferring, HAC Pharma, Janssen, Merck, Mitsubishi, Norgine, Takeda The Lancet Gastroenterology and Hepatology. 2020. Epub ahead of print